Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study

LESSONS LEARNED: Recruitment of patients with advanced hepatocellular carcinoma and Child‐Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging. Patients with Child‐Pugh B liver cirrhosis have high rates of cirrhosis‐related adverse events. BACKGROUND: Few data are ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Labeur, Tim A., Achterbergh, Roos, Takkenberg, Bart, Van Delden, Otto, Mathôt, Ron, Klümpen, Heinz‐Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485346/
https://www.ncbi.nlm.nih.gov/pubmed/31645371
http://dx.doi.org/10.1634/theoncologist.2019-0718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485346/
https://www.ncbi.nlm.nih.gov/pubmed/31645371
http://dx.doi.org/10.1634/theoncologist.2019-0718

Ejemplares similares